Edition:
United States

Erytech Pharma SA (ERYP.OQ)

ERYP.OQ on NASDAQ Stock Exchange Global Select Market

21.51USD
16 Feb 2018
Change (% chg)

$0.05 (+0.23%)
Prev Close
$21.46
Open
$21.51
Day's High
$21.51
Day's Low
$21.51
Volume
100
Avg. Vol
--
52-wk High
$30.48
52-wk Low
$17.50

Chart for

About

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Erytech Pharma ‍announces pricing of global offering of 5.4 mln new ordinary shares​

* ‍ANNOUNCES PRICING OF GLOBAL OFFERING TO SPECIFIED CATEGORIES OF INVESTORS OF AGGREGATE OF 5.4 MILLION NEW ORDINARY SHARES​

Nov 10 2017

BRIEF-Erytech Pharma announces trading suspension of its ordinary shares on Euronext paris​

* ERYTECH ANNOUNCES TRADING SUSPENSION OF ITS ORDINARY SHARES ON EURONEXT PARIS

Nov 10 2017

BRIEF-Erytech Pharma 9M net loss widens to 20.8 million euros

* ANNOUNCED ON MONDAY 9M NET LOSS OF EUR 20.8 MLN VS PROFIT OF EUR 16.1 MLN YEAR AGO

Nov 07 2017

BRIEF-Erytech Pharma sees U.S. IPO of up to 4.26 mln ordinary shares in form of ADSs

* Erytech Pharma SA sees U.S. IPO of up to 4.26 million ordinary shares in form of American Depositary Shares, or ADSs‍​ - sec filing

Nov 06 2017

BRIEF-Erytech Pharma ‍announces resubmission of european marketing authorization application for GRASPA

* ‍ANNOUNCES RESUBMISSION OF EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR GRASPA IN ACUTE LYMPHOBLASTIC LEUKEMIA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 10 2017

BRIEF-Erytech Pharma files for U.S. IPO of up to $100 mln of ADSS

* Erytech Pharma Sa files for U.S. IPO of up to $100 million of ADSS - SEC filing‍​

Oct 06 2017

BRIEF-Erytech Pharma H1 net loss widens to ‍​14.0 million euros

* ERYTECH REPORTS FIRST HALF 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Sep 11 2017

BRIEF-Erytech Pharma's complete results demonstrate statistically improvement in overall survival and progression-free survival ‍​

* COMPLETE DATA DEMONSTRATE A STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL ‍​

Sep 08 2017

Earnings vs. Estimates